Dianthus Therapeutics (NASDAQ:DNTH) Trading 7.4% Higher – Here’s What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price was up 7.4% during trading on Monday . The company traded as high as $20.31 and last traded at $20.95. Approximately 42,144 shares traded hands during trading, a decline of 84% from the average daily volume of 259,438 shares. The stock had previously closed at $19.50.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on DNTH. HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Guggenheim reissued a “buy” rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Wedbush reaffirmed an “outperform” rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $54.33.

Dianthus Therapeutics Stock Up 4.7 %

The company’s fifty day moving average is $20.24 and its 200 day moving average is $23.06. The stock has a market cap of $655.69 million, a PE ratio of -8.16 and a beta of 1.62.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.04. The company had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Equities analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in DNTH. MetLife Investment Management LLC grew its position in Dianthus Therapeutics by 3.1% in the 4th quarter. MetLife Investment Management LLC now owns 14,372 shares of the company’s stock worth $313,000 after purchasing an additional 433 shares during the last quarter. Invesco Ltd. increased its stake in shares of Dianthus Therapeutics by 7.4% during the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company’s stock valued at $251,000 after acquiring an additional 790 shares during the period. SG Americas Securities LLC raised its stake in shares of Dianthus Therapeutics by 9.2% in the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock worth $210,000 after buying an additional 814 shares in the last quarter. Barclays PLC boosted its stake in Dianthus Therapeutics by 2.6% during the fourth quarter. Barclays PLC now owns 42,766 shares of the company’s stock valued at $933,000 after buying an additional 1,082 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Dianthus Therapeutics by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company’s stock worth $3,641,000 after acquiring an additional 1,092 shares during the period. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.